PURPOSE: To determine the capacity and kinetics of the binding between triamcinolone acetonide (TA) and the ocular pigment for a better understanding of the transscleral delivery. METHODS: In the in vitro study, natural melanin (sepia officinalis, Sigma-Aldrich) was incubated at 37°C with different concentrations of TA and the binding capacity/binding affinity was measured. The TA releasing profile from the melanin was also studied through repeated incubation of TA-melanin in fresh phosphate-buffed saline. In the ex vivo study, the effect of the choroidal pigment on the trans sclera/choroid permeability of TA was investigated through Franz-type vertical diffusion cells using both a TA suspension and a saturated TA solution. RESULTS: The amount of TA bound to melanin increases with the increase of the TA concentration and with an increase in the incubation time. A Scatchard analysis revealed that the maximum number of moles of TA bound to melanin is predicted to be 22.43 nmol/mg, with a binding affinity of K=2.4×10(-5) nM(-1). TA released from a pigment showed a fast phase within the first 24 h and a slow phase thereafter. About 40% of the bound TA released in the first day and 73.94% of accumulative release was observed after 5 days. The TA suspension showed more TA penetration through the scleral-choroid complex than the saturated solution (P=0.0104). The apparent permeability coefficients for the suspension across the sclera-choroid of pigmented and albino rabbits are 7.48±1.53×10(-6) cm/s and 10.78±2.49×10(-6) cm/s, respectively. CONCLUSIONS: TA can bind to and release from the ocular pigment, which may extend the TA ocular half-life and therapeutic duration when TA is delivered through a subtenon injection. A further in vivo study is warranted to validate the findings and to quantitate the magnitude of the difference between pigmented and albino animals.
PURPOSE: To determine the capacity and kinetics of the binding between triamcinolone acetonide (TA) and the ocular pigment for a better understanding of the transscleral delivery. METHODS: In the in vitro study, natural melanin (sepia officinalis, Sigma-Aldrich) was incubated at 37°C with different concentrations of TA and the binding capacity/binding affinity was measured. The TA releasing profile from the melanin was also studied through repeated incubation of TA-melanin in fresh phosphate-buffed saline. In the ex vivo study, the effect of the choroidal pigment on the trans sclera/choroid permeability of TA was investigated through Franz-type vertical diffusion cells using both a TA suspension and a saturated TA solution. RESULTS: The amount of TA bound to melanin increases with the increase of the TA concentration and with an increase in the incubation time. A Scatchard analysis revealed that the maximum number of moles of TA bound to melanin is predicted to be 22.43 nmol/mg, with a binding affinity of K=2.4×10(-5) nM(-1). TA released from a pigment showed a fast phase within the first 24 h and a slow phase thereafter. About 40% of the bound TA released in the first day and 73.94% of accumulative release was observed after 5 days. The TA suspension showed more TA penetration through the scleral-choroid complex than the saturated solution (P=0.0104). The apparent permeability coefficients for the suspension across the sclera-choroid of pigmented and albino rabbits are 7.48±1.53×10(-6) cm/s and 10.78±2.49×10(-6) cm/s, respectively. CONCLUSIONS:TA can bind to and release from the ocular pigment, which may extend the TA ocular half-life and therapeutic duration when TA is delivered through a subtenon injection. A further in vivo study is warranted to validate the findings and to quantitate the magnitude of the difference between pigmented and albino animals.
Authors: Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman Journal: Invest Ophthalmol Vis Sci Date: 2004-11 Impact factor: 4.799
Authors: J Ambati; C S Canakis; J W Miller; E S Gragoudas; A Edwards; D J Weissgold; I Kim; F C Delori; A P Adamis Journal: Invest Ophthalmol Vis Sci Date: 2000-04 Impact factor: 4.799
Authors: Karen G Carrasquillo; Joseph A Ricker; Ioannis K Rigas; Joan W Miller; Evangelos S Gragoudas; Anthony P Adamis Journal: Invest Ophthalmol Vis Sci Date: 2003-01 Impact factor: 4.799
Authors: Yoo Chun Kim; Henry T Hsueh; Matthew D Shin; Cynthia A Berlinicke; Hyounkoo Han; Nicole M Anders; Avelina Hemingway; Kirby T Leo; Renee Ti Chou; HyeYoung Kwon; Matthew B Appell; Usha Rai; Patricia Kolodziejski; Charles Eberhart; Ian Pitha; Donald J Zack; Justin Hanes; Laura M Ensign Journal: Drug Deliv Transl Res Date: 2021-04-26 Impact factor: 4.617